Advertisement

Past, Present, and Future of Hemophilia Care

Despite affecting only about 20,000 people, hemophilia ranks as one of the most expensive chronic diseases in the United States, with treatment costs as...

Hemophilia Care From the Payer Perspective

Hemophilia is a costly and complex disease, and while there has been “incredible growth” in treatment options—48 products are currently on the market—the increased...

Hemophilia Care: A Future for Gene Therapy?

The first gene therapy trial conducted in 1990 generated big headlines until it was reported in 1999 that a participant in one of the...

Panel Perspectives on Hemophilia Management

To conclude the Specialty Connect, a panel was convened to discuss various perspectives on the current climate of hemophilia care and projections for the...

Patient Treatment Preference for Biologic Asthma Agents

There are limited data on patient preferences for biologic agents for the treatment of asthma. Researchers assessed patient and physician perceptions on biologic agents...

Restrictions on Opioid Prescribing Result in Outcomes Aligned with CDC Guidelines

Access to pain medications has led to the current opioid epidemic. A risk management program reconsidered utilization management to limit inappropriate opioid use and...

Comparison of Healthcare Resource Utilization for Oral and Injectable Biologic Agents for Joint and...

Patients with moderate to severe rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and psoriasis may require biologic immunotherapy, which can be administered...
Advertisement